Listing 3 - Actual negotiations

Indication:

For the treatment of patients with the following infections caused by the designated susceptible Gram-negative microorganisms

Indication:

For the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment.

Indication:

As an add-on to standard therapy for the treatment of gMG in adult patients who are AChR or MuSK antibody positive

Indication:

Adults with immunoglobulin G4-related disease

Indication:

For the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older.

Indication:

Advanced prostate cancer

Indication:

In combination with gemcitabine and platinum chemotherapy, for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).

Indication:

Generalized pustular psoriasis (GPP)

Indication:

In combination with daratumumab for the treatment of adults with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent

Indication:

For the treatment of mild to moderate ulcerative colitis